MSN Labs initiates phase III trial of molnupiravir to treat Covid-19 in India
MSN Laboratories, a leading integrated pharmaceutical company, has announced that it is now initiating phase III clinical trial of molnupiravir capsules for the treatment of Covid-19 in India
Molnupiravir To Treat Covid-19 In India | 25/05/2021 | By Darshana | 347
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy